Physician profile
Misha Denham
NPI 1689659096
$673,301.97
in general payments reported to CMS, 2019-2025
57 companies · $110K in 2025
The $110K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $79K · 2021: $92K · 2022: $114K · 2023: $75K · 2024: $87K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $235K · Travel and Lodging: $13K · Consulting Fee: $9,344 · Food and Beverage: $7,557 · Honoraria: $6,000 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $235,234.44 |
| Travel and Lodging | $13,310.03 |
| Consulting Fee | $9,343.75 |
| Food and Beverage | $7,557.32 |
| Honoraria | $6,000.00 |
| Education | $125.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $448,252.95 | 2019-2025 | Zepbound, Mounjaro, Baqsimi |
| Novo Nordisk INC | $168,790.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $22,560.26 | 2019-2025 | Afrezza |
| Merck Sharp & Dohme LLC | $16,750.67 | 2019-2021 | |
| Verity Pharmaceuticals INC. | $7,852.70 | 2024-2025 | Tlando |
| Corcept Therapeutics | $2,573.07 | 2019-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $1,531.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.18 | 2019-2025 | Jardiance |
| Abbvie INC. | $411.14 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $324.65 | 2019-2025 | |
| Insulet Corporation | $297.80 | 2019-2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $289.23 | 2019-2022 | |
| Amgen INC. | $263.69 | 2019-2025 | Tepezza, Repatha |
| Amarin Pharma, INC. | $261.81 | 2019-2022 | |
| Antares Pharma, INC. | $228.95 | 2019-2025 | Xyosted, Nocdurna, Tlando |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $207.63 | 2019-2025 | Tirosint, Licart, Tirosint |
| Tandem Diabetes Care, INC. | $176.59 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $147.39 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Becton, Dickinson and Company | $123.75 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $117.89 | 2024-2025 | Zenpep |
| Amneal Pharmaceuticals LLC | $109.28 | 2019-2024 | Unithroid |
| Currax Pharmaceuticals LLC | $104.62 | 2019-2022 | |
| Dexcom, INC. | $100.01 | 2021-2025 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $87.46 | 2023-2025 | Adthyza, Azmiro |
| Neurocrine Biosciences, INC. | $82.60 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $73.31 | 2020-2023 | |
| Cequr Corporation | $69.80 | 2022-2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $67.11 | 2021-2025 | |
| Medtronic, INC. | $61.85 | 2022-2024 | Minimed 780g, Mycarelink |
| Ascendis Pharma Endocrinology INC | $59.77 | 2023-2025 | Yorvipath |
| Abbott Laboratories | $59.61 | 2020-2023 | Freestyle Libre 2 |
| Vivus LLC | $58.45 | 2024-2025 | Pancreaze |
| Kyowa Kirin, INC. | $47.76 | 2023-2024 | Crysvita |
| Zealand Pharma US, INC. | $44.98 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $44.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.50 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.33 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $39.85 | 2020-2025 | Isturisa |
| Lifescan, INC. | $31.18 | 2022 | |
| Radius Health, INC. | $31.14 | 2019 | |
| Allergan, INC. | $26.04 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $25.58 | 2019 | |
| Embecta Corp. | $23.48 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Senseonics, Incorporated | $23.00 | 2019 | |
| Emd Serono, INC. | $22.29 | 2019 | |
| Medtronic Minimed, INC. | $21.75 | 2019 | |
| Sequel Med Tech, LLC | $20.85 | 2025 | Twiist |
| Alfasigma USA, INC. | $20.10 | 2021 | |
| Alvogen INC | $19.99 | 2025 | Teriparatide |
| Amryt Pharma Holdings LTD | $19.50 | 2020 | |
| Madrigal Pharmaceuticals | $18.93 | 2025 | Rezdiffra |
| Acerus Pharmaceuticals Corporation | $17.48 | 2020 | |
| Medicure Pharma INC. | $14.72 | 2025 | Zypitamag |
| Rhythm Pharmaceuticals, INC. | $14.58 | 2025 | Imcivree |
| Aytu Biopharma, INC. | $13.74 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.27 | 2021 | |
| Clarus Therapeutics INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misha Denham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.